Icad Competitors

ICAD Stock

USD 1.28 0.03 2.40%

Icad Inc competes with AmerisourceBergen, Abbott Laboratories, Adicet Bio, Acadia Healthcare, and Addus HomeCare; as well as few others. The company conducts business under Health Care Technology sector and is part of Health Care industry. Analyzing Icad competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Icad to its intrinsic valuation because they are able to contrast its competitors on a relative basis.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Icad competition on your existing holdings. Check out Icad Correlation with its peers.For information on how to trade Icad Stock refer to our How to Trade Icad Stock guide.

As of March 26, 2023, Return on Investment is expected to decline to -31.7. In addition to that, Return on Average Assets is expected to decline to -0.16. Icad Goodwill and Intangible Assets are projected to decrease significantly based on the last few years of reporting. The past year's Goodwill and Intangible Assets were at 8.14 Million. The current year Revenue to Assets is expected to grow to 0.54, whereas Current Assets are forecasted to decline to about 47.8 M.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Icad's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Icad in the context of predictive analytics.

Hype

Prediction

Low	Estimated Value	High
0.06	1.28	7.77

Details

Intrinsic

Valuation

Low	Real Value	High
0.12	2.48	8.97

Details

Naive

Forecast

Low	Next Value	High
0.021466	1.07	7.57

Details

4 Analysts

Consensus

Low	Target Price	High
5.00	6.25	8.00

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Icad. Your research has to be compared to or analyzed against Icad's peers to derive any actionable benefits. When done correctly, Icad's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Icad Inc.

Icad Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Icad and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Icad and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Icad Inc does not affect the price movement of the other competitor.

Related Correlations

	ABC	ABT	ACET	ACHC	ADUS	AEMD	AHCO	AIH	ALGN
ABC		0.71	0.5	0.84	0.12	-0.27	0.65	0.23	-0.82	ABC
ABT	0.71		0.77	0.89	0.43	0.22	0.78	0.59	-0.5	ABT
ACET	0.5	0.77		0.75	0.51	0.29	0.7	0.59	-0.32	ACET
ACHC	0.84	0.89	0.75		0.45	0.13	0.92	0.45	-0.58	ACHC
ADUS	0.12	0.43	0.51	0.45		0.7	0.58	0.49	0.24	ADUS
AEMD	-0.27	0.22	0.29	0.13	0.7		0.37	0.51	0.63	AEMD
AHCO	0.65	0.78	0.7	0.92	0.58	0.37		0.48	-0.3	AHCO
AIH	0.23	0.59	0.59	0.45	0.49	0.51	0.48		-0.07	AIH
ALGN	-0.82	-0.5	-0.32	-0.58	0.24	0.63	-0.3	-0.07		ALGN
	ABC	ABT	ACET	ACHC	ADUS	AEMD	AHCO	AIH	ALGN

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Risk-Adjusted Indicators

Nowadays, there is a big difference between Icad Stock performing well and Icad company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Icad's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Information Ratio	Expected Shortfall	Potential Upside	Value At Risk	Maximum Drawdown
ABC	0.91	(0.09)	0.00	(0.21)	0.00	(0.06)	0.00	1.63	(1.64)	6.89	AmerisourceBergen Profile AmerisourceBergen Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
ABT	0.97	(0.10)	0.00	(0.14)	0.00	(0.08)	0.00	1.79	(2.04)	5.20	Abbott Laboratories Profile Abbott Laboratories Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
ACET	3.21	(0.42)	0.00	(0.31)	0.00	(0.1)	0.00	6.68	(8.18)	24.84	Adicet Bio Profile Adicet Bio Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
ACHC	1.20	(0.22)	0.00	(0.23)	0.00	(0.12)	0.00	2.41	(2.78)	12.64	Acadia Healthcare Profile Acadia Healthcare Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
ADUS	1.26	0.02	0.01	0.00	1.62	0.014	(1.27)	2.46	(2.43)	6.60	Addus HomeCare Profile Addus HomeCare Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
AEMD	5.35	0.93	0.17	0.36	4.47	0.11	(8.24)	13.79	(7.94)	45.48	Aethlon Medical Profile Aethlon Medical Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
AHCO	2.28	(0.38)	0.00	(0.32)	0.00	(0.09)	0.00	3.63	(5.38)	31.86	Adapthealth Corp Profile Adapthealth Corp Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
AIH	4.16	0.30	0.04	0.16	5.82	0.05	(4.85)	8.59	(7.19)	31.70	Aesthetic Medical Profile Aesthetic Medical Dashboard Technical analysis Backtest News Timeline Fundamentals Trends
ALGN	2.34	0.77	0.31	0.43	1.92	0.18	(2.75)	5.24	(4.02)	32.06	Align Technology Profile Align Technology Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends

Cross Equities Net Income Analysis

Compare Icad Inc and related stocks such as AmerisourceBergen, Abbott Laboratories, Adicet Bio, Acadia Healthcare, Addus HomeCare, Aethlon Medical, Adapthealth Corp, Aesthetic Medical Intl, and Align Technology Net Income Over Time

Select Fundamental

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

ABC

719 M

433.7 M

274.2 M

(138.2 M)

1.4 B

364.5 M

1.7 B

855.4 M

(3.4 B)

1.5 B

1.7 B

2 B

2.1 B

ABT

6 B

2.6 B

2.3 B

4.4 B

1.4 B

477 M

2.4 B

3.7 B

4.5 B

7.1 B

6.9 B

5.8 B

ACET

(33.8 M)

(9.3 M)

(28.1 M)

(36.7 M)

(62 M)

(69.8 M)

(71.6 M)

ACHC

20.4 M

42.6 M

83 M

112.6 M

6.1 M

199.8 M

(175.8 M)

108.9 M

(672.1 M)

190.6 M

273.1 M

294.7 M

ADUS

7.6 M

19.1 M

12.2 M

11.6 M

12.2 M

12 M

16.4 M

25.2 M

33.1 M

45.1 M

46 M

36.9 M

AEMD

(8.1 M)

(4.9 M)

(13.4 M)

(6.8 M)

(4.9 M)

(7.3 M)

(5.7 M)

(6.2 M)

(6.4 M)

(7.9 M)

(10.4 M)

(9.4 M)

(10.1 M)

AHCO

(4.2 M)

9.7 M

23.3 M

(21.3 M)

(161.6 M)

156.2 M

69.3 M

74.8 M

AIH

50.4 M

(76.7 M)

(255.2 M)

136.3 M

(235.5 M)

(586.6 M)

(528 M)

(541.9 M)

ALGN

58.7 M

64.3 M

145.8 M

144 M

189.7 M

231.4 M

400.2 M

442.8 M

1.8 B

772 M

361.6 M

431.7 M

Icad Inc and related stocks such as AmerisourceBergen, Abbott Laboratories, Adicet Bio, Acadia Healthcare, Addus HomeCare, Aethlon Medical, Adapthealth Corp, Aesthetic Medical Intl, and Align Technology Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Icad Inc financial statement analysis. It represents the amount of money remaining after all of Icad Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Icad Competitive Analysis

The better you understand Icad competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Icad's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Icad's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	ICAD	ABC	ABT	ACET	ACHC	ADUS	AEMD	AHCO	AIH	ALGN
	2.40 1.28 Icad	3.63 156.41 AmerisourceBergen	1.04 98.05 Abbott	1.73 5.89 Adicet	1.04 70.16 Acadia	3.25 102.95 Addus	2.70 0.38 Aethlon	1.10 13.83 Adapthealth	3.05 1.35 Aesthetic	1.53 306.70 Align
Market Volatility (90 Days Market Risk)	Dangerous	Very steady	Very steady	Somewhat reliable	Very steady	Very steady	Dangerous	Not too volatile	Extremely Dangerous	Very steady
Market Performance (90 Days Performance)	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Insignificant	OK	Very Weak	Weak	Good
Odds of Financial Distress (Probability Of Bankruptcy)	Below Average	Very Low	Low	Low	Below Average	Very Low	Below Average	Close to Average	Below Average	Low
Current Valuation (Equity Enterprise Value)	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Over Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Strong Buy	Buy	Buy	Strong Buy	Hold	Buy	Buy	Buy	Strong Buy	Buy
Trade Advice (90 Days Macroaxis Advice)	Cautious Hold	Hold	Strong Hold	Cautious Hold	Cautious Hold	Hold	Cautious Hold	Cautious Hold	Cautious Hold	Strong Hold
Number of Shares Shorted	243.23 K	3.41 M	13.93 M	3.04 M	3.76 M	482.68 K	200.66 K	9.27 M	39.23 K	2.67 M
Shares Owned by Insiders	7.31	16.96	0.55	4.81	1.76	2.0	1.06	23.42	N/A	6.49
Current Ratio	3.19	0.91	1.86	16.1	1.17	2.0	9.66	1.39	0.19	1.38
Net Asset	62.19 M	56.56 B	74.44 B	338.94 M	4.99 B	937.99 M	19.42 M	5.22 B	576.94 M	5.95 B
Profit Margin	-0.5	0.0072	0.16	-2.79	0.1	0.0484	N/A	0.0233	-0.66	0.0968
EBITDA	(11.15 M)	3.16 B	10.69 B	(62.3 M)	554.78 M	83.14 M	(10.29 M)	554.68 M	(472.05 M)	768.39 M
Operating Margin	-0.5	0.0112	0.2	-2.9	0.17	0.0773	N/A	0.0728	-0.45	0.18
Current Valuation	20.38 M	35.71 B	200.5 B	479.08 M	9.21 B	1.82 B	(9.79 M)	4.93 B	99.82 M	14.33 B
Cash Flow from Operations	(9.41 M)	2.7 B	9.58 B	(51.05 M)	380.57 M	105.11 M	(9.77 M)	373.87 M	51.09 M	568.73 M
Retained Earnings	(242.03 M)	4.07 B	26.88 B	189.16 M	288.71 M	121.4 M	(102.59 M)	(25.13 M)	(261.36 M)	474.64 M
Current Asset	27.77 M	22.85 B	14.15 B	352.66 M	294.74 M	102.56 M	817 K	154.99 M	287.27 M	732.01 M
Five Year Return	N/A	1.64	1.54	3.23	N/A	N/A	N/A	N/A	N/A	N/A
Beta	1.21	0.54	0.67	2.02	1.32	0.82	1.26	0.87	-0.12	1.6
Price to Book	1.11	5.58	5.44	2.33	2.83	2.78	0.43	1.26	2.48	4.14
Shares Outstanding	25.45 M	202.26 M	1.74 B	42.95 M	91.31 M	16.13 M	22.97 M	135.45 M	43.53 M	76.61 M
Annual Yield	N/A	0.0129	0.0208	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Debt	3.16 M	4.63 B	14.52 B	22.39 M	1.36 B	131.77 M	704.05 K	2.15 B	115.67 M	120.87 M
Return On Equity	-0.34	0.5	0.19	-0.23	0.1	0.0762	-0.71	0.0346	-4.92	0.1
Price to Earning	-8.32	20.86	24.14	36.84	25.67	51.96	-1.14	25.41	4.53	29.97
Z Score	1.8	7.6	6.6	6.6	2.4	8.2	0.2	N/A	1.0	N/A
Shares Owned by Institutions	45.33	77.7	76.39	95.19	98.24	98.0	5.8	84.6	2.13	90.95
Return On Asset	-0.15	0.0294	0.0738	-0.14	0.0572	0.0488	-0.39	0.0258	-0.32	0.0691
Book Value Per Share	1.49	-0.88	21.11	6.81	31.28	39.8	0.75	16.09	-2.25	46.61
Cash and Equivalents	27.18 M	3.39 B	9.88 B	260.64 M	128.37 M	120.92 M	14.92 M	118.81 M	26.23 M	1.09 B
Price to Earnings To Growth	-0.56	1.58	18.76	0.82	1.32	1.74	N/A	1.52	N/A	10.8
Current Liabilities	14.28 M	25.28 B	9.19 B	98.91 M	290.2 M	42.19 M	1.08 M	145.86 M	248.88 M	271.67 M
Total Asset	62.19 M	56.56 B	74.44 B	338.94 M	4.99 B	937.99 M	19.42 M	5.22 B	576.94 M	5.95 B
Short Ratio	2.06	2.62	2.96	6.07	4.98	4.39	0.07	7.96	4.04	2.75
Target Price	5.0	184.07	123.97	27.63	92.25	124.43	7.38	22.4	8.93	336.6
Last Dividend Paid	N/A	1.87	1.92	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price to Sales	1.56	0.14	4.2	14.0	3.05	1.8	228.45	0.93	0.072	4.08
Market Capitalization	32.57 M	31.64 B	170.41 B	253 M	6.41 B	1.66 B	8.73 M	1.87 B	58.53 M	23.86 B
Cash per Share	1.07	16.47	5.68	6.11	1.41	7.59	0.65	0.88	1.16	13.96
Net Income	(11.24 M)	1.67 B	6.93 B	(62 M)	280.03 M	46.02 M	(10.42 M)	73.13 M	(586.62 M)	361.57 M
Earnings Per Share	-0.58	8.54	3.92	-1.34	3.01	2.95	-0.7	0.33	-3.68	4.48
Debt to Equity	0.077	N/A	0.46	0.076	0.58	0.41	0.047	1.1	4.2	0.032
Revenue	33.64 M	238.59 B	43.65 B	9.73 M	2.61 B	951.12 M	294.17 K	2.97 B	645.59 M	3.73 B
Working Capital	13.49 M	(2.43 B)	4.97 B	253.75 M	4.53 M	60.37 M	(267 K)	9.13 M	38.39 M	460.34 M
Gross Profit	24.56 M	8.33 B	24.58 B	24.99 M	1.12 B	299.74 M	294.17 K	490.83 M	269.5 M	2.64 B
Coefficient Of Variation	(3,352)	(1,388)	(1,065)	(970.88)	(782.13)	19188.3	947.58	(1,054)	2089.4	565.95
Mean Deviation	4.15	0.9125	0.9653	3.21	1.2	1.26	5.35	2.28	4.16	2.34
Jensen Alpha	(0.18)	(0.09)	(0.10)	(0.42)	(0.22)	0.019	0.9338	(0.38)	0.3049	0.7674
Total Risk Alpha	(0.040888)	(0.07)	(0.09)	(0.34)	(0.20)	0.0379	1.09	(0.30)	0.4087	0.8312
Sortino Ratio	N/A	N/A	N/A	N/A	N/A	0.0134	0.1654	N/A	0.0449	0.3054
Downside Variance	N/A	N/A	N/A	N/A	N/A	2.72	29.55	N/A	41.26	6.04
Standard Deviation	6.49	1.24	1.2	4.29	1.82	1.58	8.39	4.18	5.74	4.17
Kurtosis	12.94	2.72	(0.55)	1.14	11.27	(0.31)	7.93	26.13	3.57	25.42
Potential Upside	8.21	1.63	1.79	6.68	2.41	2.46	13.79	3.63	8.59	5.24
Treynor Ratio	(0.17)	(0.21)	(0.14)	(0.31)	(0.23)	(0.002014)	0.3562	(0.32)	0.1576	0.4256
Maximum Drawdown	50.85	6.89	5.2	24.84	12.64	6.6	45.48	31.86	31.7	32.06
Variance	42.12	1.53	1.44	18.36	3.32	2.51	70.35	17.46	32.96	17.38
Market Risk Adjusted Performance	(0.16)	(0.20)	(0.13)	(0.30)	(0.22)	0.008	0.3662	(0.31)	0.1676	0.4356
Risk Adjusted Performance	(0.019843)	(0.07)	(0.09)	(0.09)	(0.12)	0.0089	0.1093	(0.08)	0.0539	0.1758
Skewness	(2.18)	(0.12)	(0.08)	(0.13)	(2.26)	(0.20)	2.38	(4.19)	(1.10)	4.05
Semi Deviation	N/A	N/A	N/A	N/A	N/A	1.62	4.47	N/A	5.82	1.92
Information Ratio	(0.027695)	(0.06)	(0.08)	(0.1)	(0.12)	0.014	0.1072	(0.09)	0.0503	0.18
Value At Risk	(6.99)	(1.64)	(2.04)	(8.18)	(2.78)	(2.43)	(7.94)	(5.38)	(7.19)	(4.02)
Expected Short fall	N/A	N/A	N/A	N/A	N/A	(1.27)	(8.24)	N/A	(4.85)	(2.75)
Downside Deviation	N/A	N/A	N/A	N/A	N/A	1.65	5.44	N/A	6.42	2.46
Semi Variance	N/A	N/A	N/A	N/A	N/A	2.63	20.0	N/A	33.9	3.7

Icad Competition Performance Charts

Five steps to successful analysis of Icad Competition

Icad's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Icad Inc in relation to its competition. Icad's competition analysis typically involves several steps, including::

Identifying the key players in the market: This involves identifying the major competitors of Icad in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Icad's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Icad Inc, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Icad position

In addition to having Icad in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Apparel Thematic Idea Now

Apparel

Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Apparel theme has 41 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Apparel Theme or any other thematic opportunities.

View All Next

Launch

Check out Icad Correlation with its peers.For information on how to trade Icad Stock refer to our How to Trade Icad Stock guide. Note that the Icad Inc information on this page should be used as a complementary analysis to other Icad's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Icad Stock analysis

When running Icad Inc price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.

	Fund Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Piotroski F Score Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio

Is Icad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.58)

Revenue Per Share

1.163

Quarterly Revenue Growth

(0.32)

Return On Assets

(0.15)

Return On Equity

(0.34)

The market value of Icad Inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine Icad value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

Working Capital	Tangible Assets Book Value per Share
Tangible Asset Value	Sales per Share
Return on Sales	Return on Invested Capital
Return on Average Equity	Return on Average Assets
Price to Sales Ratio	Price Sales Damodaran Method
Price to Earnings Ratio	Price Earnings Damodaran Method
Price to Book Value	Payout Ratio
Profit Margin	Market Capitalization
Invested Capital Average	Invested Capital
Gross Margin	Foreign Currency to USD Exchange Rate
Free Cash Flow per Share	Free Cash Flow
Enterprise Value over EBITDA	Enterprise Value over EBIT
Enterprise Value	Average Equity
Earnings per Basic Share USD	Earnings per Diluted Share
Earnings per Basic Share	Earnings before Tax
Earnings Before Interest Taxes and Depreciation Amortization USD	EBITDA Margin
Earnings Before Interest Taxes and Depreciation Amortization EBITDA	Dividends per Basic Common Share
Dividend Yield	Debt to Equity Ratio
Current Ratio	Book Value per Share
Asset Turnover	Average Assets
Total Assets Per Share	Net Assets Per Share
Cash Flow Per Share	Revenue Per Employee
Net Income Per Employee	Return on Investment
Operating Margin	Calculated Tax Rate
Receivables Turnover	Inventory Turnover
PPandE Turnover	Cash and Equivalents Turnover
Accounts Payable Turnover	Accrued Expenses Turnover
Interest Coverage	Long Term Debt to Equity
Quick Ratio	Net Current Assets as percentage of Total Assets
Revenue to Assets

Icad Competitors

Specify up to 10 symbols:

Icad Competition Correlation Matrix

Related Correlations

Risk-Adjusted Indicators

Cross Equities Net Income Analysis

Icad Inc and related stocks such as AmerisourceBergen, Abbott Laboratories, Adicet Bio, Acadia Healthcare, Addus HomeCare, Aethlon Medical, Adapthealth Corp, Aesthetic Medical Intl, and Align Technology Net Income description

Icad Competitive Analysis

Icad Competition Performance Charts

Five steps to successful analysis of Icad Competition

Complement your Icad position

Did You Try This Idea?

Run Apparel Thematic Idea Now

Apparel

Complementary Tools for Icad Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY